This research is focused on using a rare-earth element, which is the fluorescent Tb3+ nano-ion, and the CD133 monoclonal antibody to create a CSC-targeting nanocomplex (LV3). Tb3+ nanorods were silica-surface treated and -NH2 activated before being conjugated with the monoclonal antibody (mAb) against CD133, a typical CSC surface marker . |